Skip to main content
All lobbying filings

LMH Strategic Solutions

LMH Strategic Solutions filed a Q3 report for Alnylam Pharmaceuticals, Inc. on October 19, 2026, reporting $50,000 in lobbying income.

Lobbying for Alnylam Pharmaceuticals, Inc. · Pharmaceutical manufacturer.

As filed: LMH STRATEGIC SOLUTIONS for ALNYLAM PHARMACEUTICALS, INC.

All filings by LMH Strategic Solutions · Everything Alnylam Pharmaceuticals, Inc. has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 19, 2026
Income
$50,000
What the client paid this registrant for the period.
Client based in
Massachusetts

Official filing document

 Lobbyists on this filing 2
  • ALANNA TEMME
    Previously held: Legislative Director, U.S. Representative Jon Porter
  • SOPHIE KHANAHMADI
    Previously held: Legislative Asst., Rep. Martha Roby; Legislative Asst., Rep. Lee Terry; Staff Asst./LC, Senator Jeff Sessions

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1
Medicare/Medicaid

General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.

 Bills named in this filing 3

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem